{
"id":"mk19_qq_q028",
"number":28,
"bookId":"qq",
"correctAnswer":"A",
"title":"Question 28",
"stimulus":[
{
"type":"p",
"hlId":"120f9d",
"children":[
"A 73-year-old man is evaluated for 2 days of widespread pruritic hives. Lesions last less than 60 minutes, but new lesions are continually appearing. He just finished a 7-day course of cephalexin for lower extremity cellulitis."
]
},
{
"type":"p",
"hlId":"257af6",
"children":[
"On physical examination, vital signs are normal; urticarial lesions are present on the face, neck, chest, flanks, and arms. There is no wheezing, mucosal lesions, or bullae."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"fff861",
"children":[
"Which of the following is the most appropriate therapy?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Fexofenadine"
}
},
{
"letter":"B",
"text":{
"__html":"Intramuscular epinephrine"
}
},
{
"letter":"C",
"text":{
"__html":"Prednisone"
}
},
{
"letter":"D",
"text":{
"__html":"Topical diphenhydramine"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"88bc37",
"children":[
"Drug-induced acute urticaria should be treated initially with elimination of the underlying medication trigger, if possible, and with symptomatic relief with a nonsedating, long-acting second-generation H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
"-blocking antihistamine."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"c559f0",
"children":[
"The patient should be treated with the histamine-blocking drug fexofenadine (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). He has acute urticaria (hives) that is most likely drug induced, given his recent exposure to cephalexin. Drug-induced acute urticaria should be treated initially with elimination of the underlying medication trigger, if possible, and with symptomatic relief with a nonsedating, long-acting second-generation H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
"-blocking antihistamine, such as fexofenadine. This patient has already completed his course of cephalexin and should be treated with fexofenadine for antihistaminic relief of the pruritis. If symptoms are severe or persist, adjunctive H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-blocking agents may be added, such as famotidine."
]
},
{
"type":"p",
"hlId":"ba95dd",
"children":[
"Intramuscular epinephrine (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is reserved for patients with life-threatening angioedema that may compromise the airway or those in anaphylaxis. If this patient exhibited dyspnea, difficulty clearing secretions, lip or tongue swelling, or hemodynamic instability, administration of epinephrine would be indicated. In this patient without instability or wheezing, epinephrine is not indicated."
]
},
{
"type":"p",
"hlId":"6612af",
"children":[
"A short course (less than 10 days) of systemic glucocorticoids such as prednisone (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") may be helpful for patients with widespread or highly symptomatic involvement, or for those who do not respond to first-line therapy. Adverse effects restrict the use of systemic glucocorticoids to patients in whom second-generation H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
"-blocking antihistamines are insufficiently helpful. Topical glucocorticoids may be of some help in highly focal urticaria but are not practical for widespread urticaria, such as this patient has."
]
},
{
"type":"p",
"hlId":"78a55c",
"children":[
"Topical antihistamines, such as topical diphenhydramine (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"), are not recommended because they are ineffective and may result in contact dermatitis."
]
}
],
"relatedSection":"mk19_b_gm_s10_4",
"objective":{
"__html":"Treat a patient with drug-induced urticaria."
},
"references":[
[
"Khan DA, Kocatürk E, Bauer A, Aygören-Pürsün E. What's new in the treatment of urticaria and angioedema. J Allergy Clin Immunol Pract. 2021;9:2170-2184. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34112473",
"target":"_blank"
},
"children":[
"PMID: 34112473"
]
},
" doi:10.1016/j.jaip.2021.03.012"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
},
"hlIds":[
"120f9d",
"257af6",
"fff861",
"88bc37",
"c559f0",
"ba95dd",
"6612af",
"78a55c"
]
}